A
Alcista
Alcista · 25%ASND
$234.42
Precio del escenario
$225.250
-1.352 (-0.60%)Al cierre
Loading chart…
- Máximo
- 226.760
- Apertura
- 226.620
- Precio medio ponderado por volumen
- 225.26
- Volumen
- 680.33K
- Capitalización
- 7.73B
- Mínimo
- 223.778
- Importe
- 153.25M
- EV/EBITDA, TTM
- 10.95
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
Análisis de IA of Ascendis Pharma A/S (ASND)
MantenerAscendis Pharma (ASND) is currently a hold. The stock is trading at $225.25, which is below the analyst price target range of $273 to $312, indicating potential upside. However, the RSI is at 43.23, suggesting the stock is nearing oversold territory, but not yet a strong buy signal. The recent positive regulatory news for TransCon CNP could drive future growth, but insider selling has increased by 565.41%, indicating potential caution from insiders. The main risk is the recent 5-day change of -1.74%, reflecting short-term volatility.
Recomendaciones de analistas (6)
+23.01% de potencial alcista
Comprar
5 Comprar
1 Mantener
0 Vender
Actual: 225.25
Mínimo
240.00
Promedio
277.08
Máximo
342.00
Raymond James
Superar al mercado
$287
2026-09-15
Raymond James
2026-09-15
Precio objetivo
$287
Superar al mercado
Oppenheimer
Superar al mercado
$312
2026-09-02
Oppenheimer
2026-09-02
Precio objetivo
$312
Superar al mercado
Morgan Stanley
Sobreponderar
$273
2026-09-01
Morgan Stanley
2026-09-01
Precio objetivo
$273
Sobreponderar
H.C. Wainwright
Comprar
$344
2026-08-31
H.C. Wainwright
2026-08-31
Precio objetivo
$344
Comprar
BofA
Comprar
$304
2026-08-31
BofA
2026-08-31
Precio objetivo
$304
Comprar
Métricas de valoración
El PER previsto actual de Ascendis Pharma A/S (ASND) es 19.84, frente a su media de 5 años de 3.27.
Escenarios de precio de Alphio AI para ASND
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ASND en cartera
Cronología de eventos
Noticias
8.510-16NewsfilterAscendis Pharma Receives Positive Opinion from EU for TransCon CNP
9.010-16stocktwitsAscendis Receives Positive Regulatory Opinion for Drug
8.009-15NASDAQ.COMAscendis Pharma Authorizes $400 Million Share Repurchase Program
9.009-09Yahoo FinanceAscendis Pharma Reports Week 52 Data on TransCon CNP Treatment
8.509-08NASDAQ.COMAscendis Pharma Unveils New Data at ESPE Congress
Preguntas frecuentes sobre ASND, respondidas por Alphio AI
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ascendis Pharma (ASND) is currently a hold. The stock is trading at $225.25, which is below the analyst price target range of $273 to $312, indicating potential upside. However, the RSI is at 43.23, suggesting the stock is nearing oversold territory, but not yet a strong buy signal. The recent positive regulatory news for TransCon CNP could drive future growth, but insider selling has increased by 565.41%, indicating potential caution from insiders. The main risk is the recent 5-day change of -1.74%, reflecting short-term volatility.
6 analysts cover ASND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 277.08.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.